24273179
BACKGROUND	We compared the immunogenicity and reactogenicity of Cervarix or Gardasil human papillomavirus ( HPV ) vaccines in adults infected with the human immunodeficiency virus ( HIV ) .
METHODS	This was a double-blind , controlled trial randomizing HIV-positive adults to receive 3 doses of Cervarix or Gardasil at 0 , 1.5 , and 6 months .
METHODS	Immunogenicity was evaluated for up to 12 months .
METHODS	Neutralizing anti-HPV-16 / 18 antibodies were measured by pseudovirion-based neutralization assay .
METHODS	Laboratory tests and diary cards were used for safety assessment .
METHODS	The HPV-DNA status of the participants was determined before and after immunization .
RESULTS	Ninety-two participants were included in the study .
RESULTS	Anti-HPV-18 antibody titers were higher in the Cervarix group compared with the Gardasil group at 7 and 12 months .
RESULTS	No significant differences in anti-HPV-16 antibody titers were found among vaccine groups .
RESULTS	Among Cervarix vaccinees , women had higher anti-HPV-16 / 18 antibody titers compared to men .
RESULTS	No sex-specific differences in antibody titers were found in the Gardasil group .
RESULTS	Mild injection site reactions were more common in the Cervarix group than in the Gardasil group ( 91.1 % vs 69.6 % ; P = .02 ) .
RESULTS	No serious adverse events occurred .
CONCLUSIONS	Both vaccines were immunogenic and well tolerated .
CONCLUSIONS	Compared with Gardasil , Cervarix induced superior vaccine responses among HIV-infected women , whereas in HIV-infected men the difference in immunogenicity was less pronounced .

